Kim Boesen (K Boesen)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Drug Administration

Attention Deficit Hyperactivity Disorder

Clinical Practice

Top Venues

Epidemiology and psychiatric sciences

Journal of evaluation in clinical practice

Journal of the Royal Society of Medicine

Research integrity and peer review

This page only lists publications with an associated author ORCID identifier.

Publications

Kim Boesen, P C Gøtzsche, John P A Ioannidis
Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status. Epidemiology and psychiatric sciences 33 (2024)
Kim Boesen, P C Gøtzsche, John P A Ioannidis
Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status. Epidemiology and psychiatric sciences 33 (2024)
Kim Boesen, P C Gøtzsche, John P A Ioannidis
Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status. Epidemiology and psychiatric sciences 33 (2024)
Kim Boesen, P C Gøtzsche, John P A Ioannidis
Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status. Epidemiology and psychiatric sciences 33 (2024)
Kim Boesen, P C Gøtzsche, John P A Ioannidis
Requesting conflicts of interest declarations from the European Medicines Agency: 3-year follow-up status. Epidemiology and psychiatric sciences 33 (2024)
Kim Boesen, John P A Ioannidis
Medical advertisements and scientific journals: Time for editors and publishers to take a stance. Journal of evaluation in clinical practice (2023)
Kim Boesen, Karsten Juhl Jørgensen, Peter C Gøtzsche
The US Food and Drug Administration's authorisation of Purdue's controlled-release methylphenidate for adult ADHD: comments on the regulatory practice. Journal of the Royal Society of Medicine 114 (8) (2021)
Kim Boesen, Anders Lykkemark Simonsen, Karsten Juhl Jørgensen, Peter C Gøtzsche
Cross-sectional study of medical advertisements in a national general medical journal: evidence, cost, and safe use of advertised versus comparative drugs. Research integrity and peer review 6 (1) (2021)
Kim Boesen, Peter C Gøtzsche, John P A Ioannidis
EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations. Epidemiology and psychiatric sciences 30 (2021)